Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The health industry witnesses significant developments as Hims & Hers acquires UK startup Zava, Sanofi plans a $9.5 billion ...

Braskem S.A. (São Paulo, Brazil) and Ardent Process Technologies (New Castle, Del.) announced the successful completion of ...

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

Vantive is putting more money toward research, development, and manufacturing. Other health industry news is on Advocate Health, Centene, Ballad Health, Sanofi, and more.